June 24, 2026

Lilly Halves €2.3B Alzey Germany Plant on Dynamic Manufacturer Rebate, White House Calls STAT Reporter Names Over Retatrutide Story, PCAC Oral Testimony Deadline June 30, ML-Discovered Anti-Pseudomonas AMPs

Lilly halves Alzey plant on German pricing reform; White House escalates retatrutide pushback; PCAC oral testimony deadline June 30; anti-Pseudomonas AMPs.

5 stories · Covering industry, regulatory, research

Editor's Note

BIO 2026 Day 3 in San Diego ran in the shadow of two stories that turned overnight. Lilly confirmed it is cutting its planned €2.3 billion Alzey, Germany injectable plant by half, citing Berlin's proposed 'dynamic manufacturer rebate' and broader healthcare reform. Capacity that was going to land in Rhineland-Palatinate now redirects to the US, most likely to Lilly's Pennsylvania site. The German cut crystallizes a pattern: as Europe pushes IRA-style price pressure, GLP-1 manufacturing tilts back toward US labor and US capital. Meanwhile the FDA-Lilly retatrutide compassionate-use story moved from denial to escalation. White House senior deputy press secretary Kush Desai called STAT News reporter Lizzy Lawrence 'an unserious gossip columnist' after she reported he never explicitly denied that President Trump was the 79-year-old patient. The political controversy is now louder than the underlying access-equity question. On the regulatory calendar, the PCAC oral-testimony registration deadline lands June 30 and the public docket closes July 22, six days before the July 23-24 meeting that votes on 503A bulks list eligibility for BPC-157, KPV, TB-500, MOTS-C, Emideltide/DSIP, Semax, and Epitalon. A new Frontiers in Pharmacology machine-learning paper externally validated 124 antimicrobial peptides against Pseudomonas aeruginosa, a reminder that AMP discovery is advancing in parallel to the GLP-1 headlines. STAT's June 24 BIO Readout column also surfaced fresh color on the Lilly-Chai AI biologics pact and the Lilly-Astellas bid for Sangamo's assets in bankruptcy.

Industry

Eli Lilly Cuts Planned €2.3B Alzey, Germany GLP-1 Manufacturing Plant in Half: Jobs Drop from 1,000 to 500, Capital Redirects to US Amid German 'Dynamic Manufacturer Rebate' Reform

Eli Lilly confirmed in reporting on June 22-23, 2026 that it is halving its planned €2.3 billion (US$2.7 billion) investment at the under-construction Alzey, Rhineland-Palatinate injectable manufacturing site, reducing planned headcount from approximately 1,000 to 500 and pushing the redirected capital toward US sites, most likely Lilly's Pennsylvania facility. The plant produces injectable GLP-1 drugs Mounjaro (tirzepatide for type-2 diabetes), Zepbound (tirzepatide for obesity), and Trulicity (dulaglutide), and is still scheduled to open in 2027 at the reduced capacity. Lilly cited Germany's proposed healthcare reform legislation, particularly a 'dynamic manufacturer rebate' that would automatically lower drug reimbursements as utilization climbs. Boehringer Ingelheim is also slashing planned German investment by at least $1 billion, and Pfizer CEO Albert Bourla has signaled a reassessment. Lilly's CEO David Ricks told the German government the company 'can no longer commit to the full vision for Alzey.' The cut arrives the same week as STAT's retatrutide compassionate-use story, sharpening the contrast between Lilly's expanding US capital deployment and tightening European pricing.

#eli-lilly #alzey #germany #glp-1-manufacturing #dynamic-manufacturer-rebate #tirzepatide #zepbound #mounjaro #pricing-reform

Regulatory

White House Senior Deputy Press Secretary Kush Desai Escalates Retatrutide Compassionate-Use Pushback: Calls STAT's Lizzy Lawrence 'An Unserious Gossip Columnist' as Speculation About Trump Application Spreads

Following STAT News reporter Lizzy Lawrence's June 23 scoop that the FDA and Eli Lilly granted compassionate-use retatrutide access to a 79-year-old patient on the application of NIH senior clinician Dr. Ranganath Muniyappa, the White House response intensified June 23-24. Senior deputy press secretary Kush Desai posted on X that 'this application was not for the President' but did not explicitly deny that Trump (who turned 80 on June 14) had separately applied. After Lawrence reported the non-denial, Desai publicly called her 'an unserious gossip columnist.' The White House rapid response team added: 'No, it wasn't President Trump — and you people are truly sick and deranged.' The escalation moves the story from a closed regulatory-access question to an active political controversy, with outlets including The Hill, IBTimes UK, Slate, MS NOW, Hello Magazine, Tech Times, and The New Republic running parallel coverage. Outside medical experts continue to question whether refractory obesity plus OSA plus pulmonary hypertension meets the FDA's compassionate-use threshold typically reserved for immediately life-threatening illness.

#retatrutide #white-house #trump #compassionate-use #stat-news #kush-desai #lizzy-lawrence #access-equity

Regulatory

FDA Pharmacy Compounding Advisory Committee (PCAC) Oral-Testimony Registration Deadline June 30, 2026: Written Docket FDA-2025-N-6895 Closes July 22 Ahead of July 23-24 503A Bulks List Vote on BPC-157, KPV, TB-500, MOTS-C, Emideltide/DSIP, Semax, Epitalon

The FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 at the agency's White Oak campus (Silver Spring, Maryland) reaches its first procedural cutoff next Tuesday: June 30, 2026 is the deadline to register for oral testimony in the public-comment portion of the meeting. Written comments to docket FDA-2025-N-6895 at regulations.gov must arrive by 11:59 PM ET July 22, 2026 (one day before the meeting opens). The Committee will discuss BPC-157, KPV, TB-500, and MOTS-C on Day 1 (July 23) and Emideltide/DSIP, Semax, and Epitalon on Day 2 (July 24). All seven peptides came off FDA Category 2 effective April 23, 2026. PCAC recommendations are advisory: the agency makes the final 503A bulks list decision, and the Hims & Hers (HIMS) stock breakout above $30 reflected market consensus that the July vote will tilt toward eligibility. Lengea Law and PeptideClarity have both published prescriber-facing trackers ahead of the meeting.

#pcac #fda #503a #peptide-compounding #bpc-157 #kpv #tb-500 #mots-c #emideltide #semax #epitalon #docket

Research

Frontiers in Pharmacology (June 2026): Machine-Learning Model Identifies Novel Antimicrobial Peptides Against Pseudomonas aeruginosa Using 124 Experimentally Validated Sequences as External Validation Set

A research team published in Frontiers in Pharmacology in June 2026 a machine-learning pipeline for discovering antimicrobial peptides active against Pseudomonas aeruginosa, one of the WHO's top-priority gram-negative pathogens for new antibiotic development. The model was externally validated using 124 experimentally confirmed AMPs from recent publications. Pseudomonas aeruginosa is a leading cause of ventilator-associated pneumonia and bloodstream infection in immunocompromised patients, and the rise of carbapenem-resistant strains has narrowed remaining treatment options to colistin and ceftolozane-tazobactam. The paper sits in a broader 2026 ML-AMP wave that also includes 'Advances in the Application of Deep Learning for Antimicrobial Peptide Screening' (Agricultural Science and Food Processing) and an arxiv preprint on multilabel AMP classification benchmarks. AMP discovery is one of the few peptide-drug verticals advancing in parallel to GLP-1 headlines, with no commercial obesity-driven distortion of academic publication pipelines.

#antimicrobial-peptides #pseudomonas-aeruginosa #machine-learning #amp-discovery #frontiers-pharmacology #antibiotic-resistance

Industry

STAT News BIO 2026 Day-3 Readout (June 24): New Color on Lilly-Chai Discovery AI Biologics Pact (Chai-2 Zero-Shot Antibody Design + Purpose-Built Lilly Model) and Lilly-Astellas Stalking-Horse Bid for Sangamo Assets in Bankruptcy

STAT News' June 24, 2026 BIO Readout column (Damian Garde, Allison DeAngelis) delivered behind-the-scenes detail on Eli Lilly's January 9, 2026 collaboration with AI startup Chai Discovery for biologics design, plus an update on the Lilly-Astellas joint bid for Sangamo Therapeutics assets in bankruptcy. The Chai Discovery deal deploys the company's Chai-2 zero-shot antibody design model (reportedly achieving double-digit experimental hit rates and full de novo design capability) plus a purpose-built generative AI model trained exclusively on proprietary Lilly data and tailored to Lilly's discovery workflows. Chai closed a $130 million Series B at $1.3 billion valuation in late 2025, eighteen months after launch. On the Sangamo front, Lilly is in line to acquire Sangamo's capsid delivery platform, zinc finger platform, modular integrase platform, and prion disease program ST-506 in the bankruptcy auction; Astellas is positioned to take Fabry disease asset isaralgagene civaparvovec. BIO 2026 runs June 22-25 at the San Diego Convention Center.

#bio-2026 #eli-lilly #chai-discovery #ai-biologics #sangamo-bankruptcy #astellas #san-diego #stat-news